Mirae Asset Global Investments Co. Ltd. Reduces Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mirae Asset Global Investments Co. Ltd. cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 55.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 43,050 shares of the biotechnology company’s stock after selling 52,815 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Sarepta Therapeutics were worth $4,151,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Sarepta Therapeutics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock worth $1,039,212,000 after purchasing an additional 41,465 shares during the period. Wellington Management Group LLP boosted its stake in shares of Sarepta Therapeutics by 1.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,909,800 shares of the biotechnology company’s stock worth $473,946,000 after purchasing an additional 54,698 shares during the period. State Street Corp boosted its stake in shares of Sarepta Therapeutics by 7.9% during the 2nd quarter. State Street Corp now owns 1,913,732 shares of the biotechnology company’s stock worth $219,161,000 after purchasing an additional 139,756 shares during the period. Geode Capital Management LLC boosted its position in Sarepta Therapeutics by 3.5% in the 1st quarter. Geode Capital Management LLC now owns 1,261,971 shares of the biotechnology company’s stock valued at $173,938,000 after buying an additional 43,239 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in Sarepta Therapeutics by 40.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,171,442 shares of the biotechnology company’s stock valued at $161,461,000 after buying an additional 334,749 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SRPT has been the subject of several research reports. Evercore ISI boosted their price objective on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. Mizuho boosted their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. UBS Group boosted their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Citigroup boosted their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Finally, Royal Bank of Canada boosted their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and an average target price of $158.38.

Sarepta Therapeutics Trading Down 3.7 %

NASDAQ SRPT opened at $118.31 on Tuesday. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. The firm has a market cap of $11.11 billion, a PE ratio of -19.33 and a beta of 0.94. The company has a 50 day moving average price of $127.31 and a 200 day moving average price of $110.37. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. During the same quarter in the prior year, the business posted ($1.24) EPS. Sarepta Therapeutics’s revenue for the quarter was up 53.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.14 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the transaction, the chief financial officer now owns 39,114 shares in the company, valued at approximately $5,018,326.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the sale, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,096 shares of company stock worth $2,739,419. 7.40% of the stock is owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.